US-based spinal implant solutions provider Aurora Spine has entered a worldwide distribution and co-marketing deal with Sentio to distribute the mechanomyography (MMG) nerve mapping system.
The Sentio MMG is a surgical access tool, offering improved technology for surgeons when compared with traditional techniques.
Sentio MMG locates and maps motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
Aurora Spine CEO Trent Northcutt said: "This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies.
"We are excited about our relationship with Sentio MMG in conjunction with our VOX MIS lateral interbody system featuring TiNANO.
"The Sentio system was specifically designed to facilitate safe MMG monitoring during any minimally invasive spine surgery (MIS)."
Smart sensors in the system employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG activity, or the mechanical twitch associated with muscle contraction.
Sentio market development vice-president Sean Parker said: "Aurora’s MIS, tech-company culture fits extremely well with Sentio.
"We share a common ethos that will help drive both organizations to success as we co-market our technologies."
The system is cleared by US Food and Drug Administration (FDA) to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves.
The Sentio MMG system also has a CE Mark for use in the European Union (EU) and other markets.